Clinical trials of PUFAs in depression: State of the art

Keyphrases

• Clinical Trials 100%
• Omega-3 100%
• Depression Treatment 66%
• Polyunsaturated Fatty Acids 33%
• Placebo-controlled 33%
• Docosahexaenoic Acid 33%
• Eicosapentaenoic Acid 33%
• Bipolar Disorder 33%
• Cardiovascular Disease 33%
• Special Populations 33%
• Antidepressants 33%
• Active Ingredients 33%
• Depressive Disorder 33%
• Registration Trial 33%
• Psychiatry 33%
• Number of Participants 33%
• Acid Treatment 33%
• Unipolar Depression 33%
• Psychopharmacology 33%
• Investigator-initiated 33%
• Federal Drug Administration 33%
• Omega Fatty Acids 33%
• Outstanding Issues 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Omega-3 Fatty Acid 100%
• Disease 33%
• Docosahexaenoic Acid 33%
• Fatty Acid 33%
• Icosapentaenoic Acid 33%
• Placebo 33%
• Epileptic Absence 33%
• Cardiovascular Disease 33%
• Major Depression 33%
• Bipolar Disorder 33%
• Antidepressant 33%
• Polyunsaturated Fatty Acid 33%
• Drug Administration 33%
• Psychopharmacology 33%

Neuroscience

• Omega 3 Fatty Acid 100%
• Treatment of Depression 66%
• Docosahexaenoic Acid 33%
• Fatty Acids 33%
• Icosapentaenoic Acid 33%
• Bipolar Disorder 33%
• Major Depressive Disorder 33%
• Epileptic Absence 33%
• Placebo 33%
• Depression 33%
• Polyunsaturated Fatty Acid 33%
• Antidepressant 33%
• Psychiatry 33%
• Psychopharmacology 33%